DRRX vs. CTMX, SELB, SGMT, ATOS, RZLT, ALIM, RIGL, RNAC, CNTX, and PRQR
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include CytomX Therapeutics (CTMX), Selecta Biosciences (SELB), Sagimet Biosciences (SGMT), Atossa Therapeutics (ATOS), Rezolute (RZLT), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Cartesian Therapeutics (RNAC), Context Therapeutics (CNTX), and ProQR Therapeutics (PRQR). These companies are all part of the "medical" sector.
DURECT (NASDAQ:DRRX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
CytomX Therapeutics has a net margin of 13.87% compared to DURECT's net margin of -279.77%. CytomX Therapeutics' return on equity of -30.70% beat DURECT's return on equity.
28.0% of DURECT shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 4.3% of DURECT shares are owned by insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, CytomX Therapeutics had 8 more articles in the media than DURECT. MarketBeat recorded 10 mentions for CytomX Therapeutics and 2 mentions for DURECT. DURECT's average media sentiment score of 0.94 beat CytomX Therapeutics' score of 0.61 indicating that DURECT is being referred to more favorably in the media.
CytomX Therapeutics received 56 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 66.07% of users gave CytomX Therapeutics an outperform vote while only 65.15% of users gave DURECT an outperform vote.
DURECT presently has a consensus target price of $27.50, indicating a potential upside of 1,937.04%. CytomX Therapeutics has a consensus target price of $5.77, indicating a potential upside of 229.86%. Given DURECT's stronger consensus rating and higher possible upside, equities analysts plainly believe DURECT is more favorable than CytomX Therapeutics.
CytomX Therapeutics has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
DURECT has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
Summary
CytomX Therapeutics beats DURECT on 13 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
